Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)

Biologics such as risankizumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described according to a 'one dose fits all' dosing regimen, leading to potential over-and undertreatment. In this study the investigators aim to investigate the predictive value of early serum trough levels of risankizumab and determine the therapeutic window of risankizumab in psoriasis patients.

Inclusion Criteria:Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasisParticipants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.Exclusion Criteria:Participants who have currently a predominant nonplaque form of psoriasisParticipants who are pregnant, nursing or planning a pregnancyParticipants who are unable or unwilling to undergo multiple venapuncturesParticipants who are treated according to a different dosing schedule than standard dosing of risankizumab